论文部分内容阅读
为了提高过继性免疫治疗(AIT)疗效,查清体内激活的外周血T 淋巴细胞(PBT)是否已获得溶细胞活性是极其重要的。观察了9例原发性肺癌病人PBT 的溶细胞活性。病人皆采用外科手术辅以低剂量rlL-2和LAK 细胞的过继性免疫治疗,在外周血淋巴细胞增高时,采血并分离其PBT,用抗-CD_3或抗-TCR 以及FcR~+肿瘤靶细胞系统观察PBT 的靶向细胞毒活性(Targeted Cytoto-xicity)。研究结果显示:在AIT 之后24～48小时,所有病人外周血淋巴细胞(PBC)均明显增高,比治疗前提高2.3～5.6倍。表型分析显示,在AIT 之后,CD_3~+细胞部
In order to improve the therapeutic effect of adoptive immunotherapy (AIT), it is very important to find out whether the activated peripheral blood T lymphocytes (PBT) in vivo have acquired the cytolytic activity. The cytolytic activity of PBT in 9 patients with primary lung cancer was observed. Patients were treated surgically with adoptive immunotherapy of low doses of rlL-2 and LAK cells. When peripheral blood lymphocytes increased, blood samples were collected and PBTs were isolated. Anti-CD_3 or anti-TCR and FcR ~ + tumor target cells The targeted cytotoxic activity of PBT was systematically observed (Targeted Cytoto-xicity). The results showed that peripheral blood lymphocytes (PBC) were significantly increased in all patients 24 to 48 hours after AIT, 2.3 to 5.6 times more than before treatment. Phenotypic analysis showed that after AIT CD3 ~ + cells